Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease

2010/09/24 by Takhar Kasumov, John M. Edmison, Srinivasan Dasarathy +4 · 21 citations
Medicine · #Diet, Metabolism, and Disease #Cardiovascular Function and Risk Factors #Bariatric Surgery and Outcomes

paper · doi:10.1016/j.metabol.2010.07.027

Cited by

• Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease. [europepmc]
• A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease. [europepmc]
• Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. [europepmc]
• Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease. [europepmc]
• Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). [europepmc]
• The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease. [europepmc]
• Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. [europepmc]
• Association of Asymmetric Dimethylarginine and Nitric Oxide with Cardiovascular Risk in Patients with End-Stage Liver Disease. [europepmc]
• Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. [europepmc]
• Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. [europepmc]
• Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. [europepmc]
• Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study. [europepmc]
• Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review. [europepmc]
• Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease. [europepmc]
• Discriminatory Changes in Circulating Metabolites as a Predictor of Hepatocellular Cancer in Patients with Metabolic (Dysfunction) Associated Fatty Liver Disease. [europepmc]
• Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease. [europepmc]
• Non-alcoholic fatty liver disease and compromised endothelial function in people with type 2 diabetes. [europepmc]
• Significance of fatty liver index to detect prevalent ischemic heart disease: evidence from national health and nutrition examination survey 1999-2016. [europepmc]
• Nonalcoholic fatty liver disease is an independent risk factor for ischemic stroke after revascularization in patients with Moyamoya disease: a prospective cohort study. [europepmc]
• Association between fatty liver index and cardiometabolic multimorbidity: evidence from the cross-sectional national health and nutrition examination survey. [europepmc]
• Life-Course Regulation of Health and Disease by Nitric Oxide: Mechanistic Insights. [europepmc]